Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Activation of vasculature associated stem cells and muscle stem cells for the repair and maintenance of muscle tissue (ENDOSTEM)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: France,Italy,Italy,Switzerland,Germany,Spain,Germany,United Kingdom,Spain,United Kingdom
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2014-12-31
Duration (months): 60.0
Total project cost (EUR): 16340569.28
EU funding (EUR): 11997580.0
Participants: 22
Project status: CLOSED

We propose to develop new strategies to mobilize skeletal muscle tissue-associated stem cells as a tool for efficient tissue repair. This will be combined with exploring novel approaches that limit tissue damage, and will focus on agents that modify muscle and muscle vasculature progenitor cells. These molecules include nitric oxide associated with non-steroidal anti-inflammatory drugs, HMGB1, Cripto, NAC, and present and improved deacetylase inhibitors. Three clinical trials will be run in tandem with efforts to dissect the underlying mechanisms of action. Importantly, we have already initiated a monocentric clinical trial that focuses on the efficacy of NO-donors plus NSAIDs in muscle pathologies. Our efforts will be complemented by novel biodelivery systems for effective targeting. Our efforts will be complemented by novel biodelivery systems for effective targeting. The most promising drugs, used alone or in combination, will be first validated in small and large animal models. Our project brings together leading investigators to examine how vascular and muscle progenitors participate in postnatal growth and muscle tissue repair. A key issue that this project addresses is the tissue environment in which endogenous stem cells are activated. We propose that muscle degeneration and fibrosis provokes altered vascularization and immune responses, which eventually affect negatively stem cell functions. Molecules that can be used to therapeutically target these key cells, and their communication with neighboring vascular, inflammatory and fibrotic cell types, will lead to more effective approaches to muscle regenerative medicine and to novel cures for degenerative diseases, including atherosclerosis, vascular damage in diabetes and in peripheral ischemic vascular disease.

Keywords: stem cells,biopharmaceuticals,clinical validation,antioxidant,muscle,vasculature
Predicting antibiotic resistance (PAR)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Sweden,Denmark,Spain,United Kingdom,Switzerland,France,United Kingdom,United Kingdom,United Kingdom,United Kingdom
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-04-01
End date: 2013-03-31
Duration (months): 36.0
Total project cost (EUR): 7950621.0
EU funding (EUR): 6000000.0
Participants: 12
Project status: CLOSED

The aim of this proposal is to describe and predict the dynamics of antibiotic resistance development at the level of the drug target, the microbe and the host. That is, we want to generate the knowledge required to be able to connect resistance mechanism --> bacterial physiology and fitness --> bacterial survival within a host --> bacterial spread between hosts. To achieve this goal we will develop quantitative models that can capture these complex dynamics, obtain relevant parameter values and validate the models by testing them in suitable in vitro, animal models and in clinical settings. We will address three main areas (A-C) in 11 different work packages. A. Formation and emergence of resistant bacteria (WPs1-5). The rate of formation of resistant mutants is one major determinant that influences how rapidly resistant mutants will appear in response to antibiotic use. Depending on the type of resistance mechanism factors such as rates of mutation, recombination and transfer of plasmids will be important. In WPs 1-5 we will experimentally determine these rates for different combinations of bacterial species and resistance mechanisms. B. Survival and persistence of resistant strains (WPs 6-8). A key factor that affects the survival and persistence of resistant strains is the impact the particular resistance mechanism has on bacterial physiology, including bacterial growth rate and virulence. We want to determine the effect of various drug resistance mechanisms on cellular physiology and fitness to establish a link between the molecular alteration and potential effects at the cellular level. C. Transmission of resistant strains (WPs 9-11). Finally we want to understand and predict how resistance mechanisms (by their effect on bacterial physiology) influence the ability of the bacteria to be transmitted between hosts. Thus, we aim to generate both animal and clinical determinations of how resistance affects transmissibility and testable mathematical models.

Keywords: antibiotic resistance,mutation rates,mutators,recombination,horizontal gene transfer,gene amplification,fitness costs,virulence,transmission,animal and clinical studies
Protein Binders for Characterisation of Human Proteome Function: Generation, Validation, Application (AFFINOMICS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: United Kingdom,Sweden,Switzerland,Sweden,Denmark,Finland,Germany,Italy,Germany,Germany,Germany,Germany,Belgium,United Kingdom,Germany,Sweden
Call:  (FP7-HEALTH-2009-two-stage, 2009)
Start date: 2010-04-01
End date: 2015-03-31
Duration (months): 60.0
Total project cost (EUR): 14620568.35
EU funding (EUR): 11000000.0
Participants: 20
Project status: CLOSED

The Affinomics programme aims to leverage existing efforts in Europe to generate large-scale resources of validated protein-binding molecules (‘binders’) as affinity reagents for characterisation of the human proteome and to apply them in comprehensive structural and functional analyses of protein expression, interactions and complexes. Proteome targets will be focused on five categories of inter-related human proteins involved in signal transduction, cell regulation and cancer, namely protein kinases, SH2 domain-containing proteins, protein tyrosine phosphatases, proteins somatically mutated in cancers and candidate cancer biomarkers. Binders to about 1000 protein targets will be made over the course of the programme. A high throughput, coordinated production pipeline for antigens and binders will be established. Target antigens will be expressed in three forms, as folded full-length proteins or domains, as large peptide fragments (PrESTs) based on low homology to other human proteins and as small peptides, in some cases phosphorylated. Binder types to be generated include affinity-purified polyclonal antibodies, monoclonal antibodies, recombinant antibody fragments and non-immunoglobulin scaffolds. An important aspect will be the development of highly efficient ‘next generation’ recombinant selection methods, based on phage, cell and ribosome display, capable of producing high quality binders at greater throughput and lower cost than hitherto. Systems and procedures for thorough binder validation and quality control will be established. The affinity reagents will be applied in advanced innovative and sensitive technologies for specific detection of target proteins and interacting protein complexes in cells, tissues and fluids, for improved understanding of protein function and new classes of diagnostic assays.

Keywords: human proteome,protein binder,antibody,scaffold,recombinant,cell signalling,cancer,protein interactions,protein complexes
European Consortium on Synaptic Protein Networks in Neurological and Psychiatric Diseases (EUROSPIN)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Netherlands,Israel,United Kingdom,United Kingdom,Germany,Italy,United Kingdom,Switzerland,Japan,Germany
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2014-06-30
Duration (months): 54.0
Total project cost (EUR): 15806674.27
EU funding (EUR): 11952691.0
Participants: 18
Project status: CLOSED

Signalling at nerve cell synapses - a key determinant of all aspects of brain function - depends on the function of hundreds of synaptic proteins and their interactions. Numerous recent studies showed that a wide range of neurological and psychiatric diseases are &apos;synaptopathies&apos; whose onset and progression are due to mutations of synaptic proteins and subsequent synaptic dysfunctions. EUROSPIN will pursue a multilevel systems biology approach to determine mechanistic relationships between mutations of synaptic proteins and neurological and psychiatric diseases, and to develop new diagnostic tools and therapies. Our concept is based on the current knowledge of disease genes, which we will continuously extend with new human genetic data and complement with large-scale screens of mutant mice in order to identify and characterize disease-relevant mutations in synaptic proteins and corresponding mouse models. Proteomic tools will be used to analyse the protein components of synapses, and protein interaction networks of synaptic disease gene products will be mapped systematically. In parallel, smart libraries will be employed to develop small molecules for perturbing the functions and interactions of disease gene products. Functional models of disease-relevant protein networks will be generated and used to formulate hypotheses as to how specific mutations might affect synaptic physiology and network function, and thus cause disease. These hypotheses will initially be tested in reduced systems by novel physiological and imaging methods. Well-validated disease gene products, the consequences of their dysfunction in disease, and therapeutic modifications of their dysfunction will then be studied in mouse models in vivo, applying novel electrophysiological, imaging, and behavioural techniques. The combined information obtained in the EUROSPIN program will be used for the development of new diagnostic tools and therapeutic interventions that can be tested in patients.

Keywords: synaptopathies,systems biology,chemical biology,synaptic dysfunction,neuronal networks,behaviour
European large-scale functional genomics in the rat for translational research (EURATRANS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,United Kingdom,United Kingdom,Netherlands,Germany,United Kingdom,United Kingdom,Sweden,France,Czechia,Germany,United States,Japan,Netherlands,United Kingdom,Denmark
Call:  (FP7-HEALTH-2009-two-stage, 2009)
Start date: 2010-04-01
End date: 2015-03-31
Duration (months): 60.0
Total project cost (EUR): 13695674.0
EU funding (EUR): 10500000.0
Participants: 19
Project status: CLOSED

Genetic studies in model organisms and humans, including human genome-wide association studies, have pinpointed genomic regions that contribute susceptibility to common disease. However, to date, these data have provided limited insights into the genes, molecular pathways and mechanisms underlying disease pathophysiology. The EU FP6 Euratools consortium has been a remarkable success that established significant research collaborations, expertise and infrastructure in the EU, making a major contribution to the rat focus issue of Nature Genetics (Volume 40, May 2008), which featured six papers from the consortium. These successes underpin the current project in which we will use state-of-the-art and emerging large-scale technologies and advanced computation in an expanded multi-disciplinary approach to identify gene networks and genomic mechanisms underlying common diseases. We will use the rat as a model system to identify the major functional pathways underlying human inflammatory, cardiovascular and metabolic, and behavioral disorders. Our consortium brings together world class investigators who will use next-generation sequencing technologies to generate genomic, transcriptomic and epigenomic datasets. To this, we will add cutting-edge, quantitative metabonomic and proteomic datasets to give significant depth of coverage, at multiple levels, across pathophysiological phenotypes. These datasets will be gathered, annotated and integrated in relational and dynamic models that will be used in comparative analyses to understand human gene function at the level of the molecule, cell, tissue and organism. These studies will lead to new insights into disease mechanisms, through an integrative, cross-disciplinary approach to understanding large-scale functional genomic datasets in rats and humans.

Keywords: rat functional genomics,metabonomics,proteomics,bioinformatics,data integration,disease pathways,regulatory networks,translational research,cardiovascular and inflammatory disease,behaviour
Planetary Robotics Vision Scout (PROVISCOUT)

Framework: FP7 — Cooperation
Programme: Space
Destination: Strengthening the foundations of Space science and technology
Action type: Collaborative project
Countries involved: Austria,United Kingdom,Germany,United Kingdom,Czechia,Spain,United Kingdom,Switzerland,Belgium,United Kingdom,United Kingdom
Call:  (FP7-SPACE-2009-1, 2009)
Start date: 2010-04-01
End date: 2012-09-30
Duration (months): 30.0
Total project cost (EUR): 2698481.4
EU funding (EUR): 1914224.7
Participants: 12
Project status: CLOSED

ProViScout will demonstrate the combination of vision-based autonomous sample identification & sample selection with terrain hazard analysis for a long range scouting/exploration mission on a terrestrial planet. It brings together major European groups currently working on planetary robotic vision, supported by NASA-JPL from USA. Most robotic planetary space missions performing in situ exploration of the surface and atmosphere for any planetary object outside the Earth involve a means of mobility provided by either a surface vehicle (‘rover’) or by aerial vehicles (balloons, aerobots etc.). Mobile systems are among the most critical of all space missions in requiring a rapid and robust on-site processing and preparation of scientific data to allow efficient operations for a maximum use of their limited lifetime. In future the number and variety of such platforms will require more autonomy than is feasible today, particularly in the autonomous on-site selection of and access to scientific and mission-strategic targets. ProViScout will provide the robotic vision building blocks on board of such future autonomous exploration systems. Therefore ProViScout aims to 1. build a framework for planetary robotic on-board vision processing, 2. develop the technology to autonomously select scientific sites of interest during future planetary robotic missions in order to maximize the mission value for scientific research, technology and education 3. develop a unified and generic approach for robotic vision on-board processing, namely the combination of navigation and scientific target selection 4. demonstrate the synergies and complementarities of existing solutions, and complete missing components by defining and demonstrating on-board robotic vision for a set of typical reference mission scenarios, 5. integrate all components into a framework ready for field demonstration 6. increase public awareness of planetary robotic exploration.

Keywords: space robotics,vision-based navigation,planetary exploration,science target selection,mission task planning.
Systems biology towards novel chronic kidney disease diagnosis and treatment (SYSKID)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Austria,Austria,Germany,Denmark,Germany,Netherlands,Poland,Hungary,United Kingdom,Germany,Netherlands,Italy,France,Israel,Ireland,Germany,Spain,Switzerland,Spain,Germany,Germany,Belgium,United States
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2014-12-31
Duration (months): 60.0
Total project cost (EUR): 15743594.0
EU funding (EUR): 11789534.0
Participants: 29
Project status: CLOSED

Chronic kidney disease (CKD) affects up to 10% of the population. Besides eventual progression towards end stage renal disease CKD impacts the patient’s quality of life by causing serious comorbidities including cardiovascular complications and bone metabolism disorders. On the everyday clinical level early stage diagnosis and tailored treatment of CKD are still inadequate. In addition, CKD seems not to have reached its appropriate emplacement in an epidemiological and healthcare perspective yet, and the pathophysiology of the disease on a molecular and cellular level is not well enough understood. Our sysKID consortium was installed for precisely addressing these issues: To unravel the molecular and cellular mechanisms of chronic kidney disease development, combine this information with clinical risk factors, and on this basis delineate chronic kidney disease biomarkers. These markers will allow us to perform preclinical studies of novel therapy approaches for halting disease progression, and will provide us with the materials for development and clinical evaluation of tools for early stage diagnosis as well as prognosis and treatment monitoring. sysKID assures a successful implementation of these goals by a truly international consortium of 27 leading research groups. We combine clinical know how, provide access to a huge chronic kidney disease sample and clinical data pool, and build a Systems Biology framework for chronic kidney disease by integrating molecular and cellular biology, computational biology, statistics and epidemiology. Our expert group is further complemented by a high level advisory board covering science, product development, and the patient’s perspective. sysKID implementation is structured for completing pre-clinical Proof of Concept studies of novel chronic kidney disease therapy regimes, and further for completing clinical evaluation of an epidemiological screening tool as well as of early stage chronic kidney disease diagnostic kits.

Keywords: chronic kidney disease,diabetic nephropathy,diagnostic assays,therapy regimes,omics experiments,systems biology,functional genomics,patient outcome,clinical data repositories
Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: Germany,United Kingdom,Poland,Germany,Germany,Germany,Russian Federation,Slovenia,Poland,Italy
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2009-10-01
End date: 2014-03-31
Duration (months): 54.0
Total project cost (EUR): 6241658.84
EU funding (EUR): 2999358.0
Participants: 13
Project status: CLOSED

Chronic heart failure (CHF) is a massive clinical, social and economic problem. Diabetes and obesity increase the risk of developing CHF. Cachexia is also an ominous sign. In 13 clinical and preclinical research projects, SICA-HF aims to investigate the impact of these co-morbidities in CHF patients at the clinical, vascular, cellular and molecular levels. SICA-HF will enrol &gt;1600 patients with CHF, &gt;300 patients with type 2 diabetes without CHF and &gt;150 healthy control subjects. We will ensure that 50% of subjects are women and that group mean ages are similar. Clinical investigations using standardised protocols will focus on body composition, insulin resistance, exercise capacity, cardiopulmonary reflex patterns and peripheral blood flow. Subjects will be assessed at baseline, after 4-6 months, 16-18 months and at annual intervals thereafter. Outcome variables include morbidity and mortality and data on incidence and prevalence of type 2 diabetes, obesity and cachexia among CHF patients. A strength of this proposal is that clinical and preclinical researchers will study the same patients, as blood and tissue samples from patients being clinically evaluated will be sent to partner research laboratories. Such interaction is very rare in large-scale studies and allows integration of clinical and preclinical findings. The Central Blood and DNA Banks on the EU and the Russian side of the consortium permit validation of established and investigation of novel biomarkers. Pathophysiological pathways that are found to be important in the heart failure co-morbidity interaction will be further analysed mechanistically in in-vitro and in animal models. We aim to validate clinical study results in experimental settings towards the end of the project (year 3 &amp; 4), particularly focusing on adipose tissue, skeletal muscle and (endothelial) progenitor cells. Our studies aim to enable developing tailored therapies for CHF patients with type 2 diabetes, obesity and cachexia.

Keywords: heart failure,diabetes mellitus,obesity,cachexia,body composition,neuroenedocrine activation,biomarker,morbidity,mortality
SUB nanosecond Leverage In PET/MR ImAging (SUBLIMA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Germany,Netherlands,Italy,Germany,United States,Netherlands,Switzerland,United Kingdom,Netherlands,Germany,Belgium,Germany
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-09-01
End date: 2015-02-28
Duration (months): 54.0
Total project cost (EUR): 16852561.4
EU funding (EUR): 11746804.0
Participants: 14
Project status: CLOSED

The SUBLIMA project aims at truly simultaneous, fully integrated, solid-state PET/MR technology for concurrent functional and anatomical imaging with unsurpassed image quality. It will combine the extremely sensitive functional imaging possibilities provided by PET with the excellent soft-tissue contrast and complementary functional imaging capabilities of MR. For the first time, time-of-flight (ToF) and depth-of-interaction (DoI) correction will be introduced together into a PET/MR system. SUBLIMA will also be the first to exploit the unique advantages of truly simultaneous PET/MR acquisition by enabling fully 4D MR-derived motion correction. Furthermore, artefacts seen in PET-CT will be eliminated by developing MR-based, motion-compensated PET attenuation correction. The SUBLIMA platform will thus realize a breakthrough in image quality and enable novel applications in oncology, cardio-vascular medicine, and neuro-degenerative diseases. SUBLIMA will not only introduce new methods and technologies in each important component of the imaging chain, but it will also analyse the system performance as a function of all relevant design parameters, in order to push the image quality to the physical limits by optimally merging these innovations into 7T preclinical and 3T whole-body human demonstrator systems. This integrated approach also warrants adaptation of the project results for optimum performance in stand-alone PET and SPECT applications. The consortium, lead by Philips, consists of universities, research institutes, industrial partners, and SMEs, spread over 7 different countries including the USA. While each partner has shown exceptional quality in its own field, the consortium brings together the wide and complementary range of expertise necessary to push the performance of ToF-PET/MR to the physical limits.

Keywords: solid-state pet/mr detectors,simultaneous pet/mri medical imaging,oncology,cardio-vascular diseases,neuro-degenerative diseases